- Theravance Biopharma Inc TBPH has voluntarily discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK inhibitor) in Crohn’s disease (Study 0173).
- The decision follows the planned review of trial data by the independent data monitoring committee, which determined concerns about the ongoing benefit-risk of continuing the trial.
- The committee, while, said there were no safety concerns.
- Related Link: Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study.
- Price Action: TBPH shares are down 2.80% at $7.99 during the premarket session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
